What is a Chemotherapy Iron Panel?
A chemotherapy iron panel is a set of laboratory tests used to assess iron status in cancer patients receiving chemotherapy, specifically measuring serum iron, total iron binding capacity (TIBC), transferrin saturation (TSAT), and serum ferritin to distinguish between absolute and functional iron deficiency 1.
Components and Interpretation
The panel includes four key measurements that work together to characterize iron status:
Core Laboratory Values
- Serum Iron: Direct measurement of circulating iron
- TIBC (Total Iron Binding Capacity): Reflects the blood's capacity to bind iron with transferrin
- Transferrin Saturation (TSAT): Calculated as (serum iron/TIBC) × 100, indicating how much transferrin is saturated with iron
- Serum Ferritin: Reflects total body iron stores
Clinical Significance in Cancer Patients
The chemotherapy iron panel should be performed before initiating erythropoiesis-stimulating agent (ESA) therapy to identify the type of iron deficiency present 1.
Diagnostic Thresholds
The panel distinguishes two types of iron deficiency:
Absolute Iron Deficiency:
- TSAT < 15%
- Serum ferritin < 30 ng/mL
- Indicates depleted iron stores
- May respond to iron monotherapy without ESA 1
Functional Iron Deficiency:
- TSAT < 20% (some sources use < 50%)
- Serum ferritin ≥ 30 ng/mL and ≤ 500-800 ng/mL
- Iron stores are adequate but cannot be mobilized quickly enough for erythropoiesis
- Common in cancer patients due to inflammatory cytokines and hepcidin upregulation 1, 2
Why This Panel Matters
Pathophysiology Context
Cancer and chemotherapy trigger inflammatory cytokine release that upregulates hepcidin, a molecule that blocks iron release from macrophages to transferrin 1. This creates a "functional" iron deficiency where iron is trapped in storage despite adequate total body iron. ESA therapy further accelerates this problem by stimulating rapid red blood cell production that depletes available iron faster than it can be mobilized 1.
Treatment Implications
The panel results directly guide therapy:
- Absolute iron deficiency: Intravenous iron products alone (without ESA) are recommended for iron repletion 1
- Functional iron deficiency with chemotherapy-induced anemia: ESAs should be used in addition to intravenous iron 1
- Normal iron parameters: ESA therapy alone may be considered if anemia is present
Important Caveats
Ferritin is an acute phase reactant, meaning inflammation from cancer itself can artificially elevate ferritin levels even when true iron deficiency exists 1, 2. In cancer patients with inflammation, the ferritin threshold for absolute iron deficiency should be raised to < 100 ng/mL rather than < 30 ng/mL 2.
Iron parameters are measured in less than 10% of cancer patients in real-world practice despite guideline recommendations, representing a significant gap in care 3. When measured, functional iron deficiency is the predominant finding, increasing from 54.8% to 61.6% after chemotherapy initiation 3.
Monitoring Frequency
Iron studies should be performed before treatment initiation 1. Repeat testing may be warranted if patients fail to respond to ESA therapy after 4-6 weeks, as functional iron deficiency commonly develops during treatment 1.